A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Trial Identifier: D6187C00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
Start Date: August 2025
Primary Completion Date: March 2027
Study Completion Date: April 2029
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Nedlands, AU, 6009
AU Woodville, AU, 5011
CA, ON Toronto, ON, CA, M5G 2M9
CN Changsha, CN, 410013
CN Chengdu, CN, 610041
CN Deyang, CN, 618000
CN Dongguan, CN, 523059
CN Fuzhou, CN, 350014
CN Guangzhou, CN, 510080
CN Guangzhou, CN, 510100
CN Hangzhou, CN, 310014
CN Linyi, CN, 276001
CN Mianyang, CN, 621000
CN Nanchang, CN, 330000
CN Nanchang, CN, 330006
CN Shantou, CN
CN Shenyang, CN, 110042
CN Wuhan, CN, 430022
CN Zhengzhou, CN, 450008
CN Zhengzhou City, CN, 450000
CN zhuhai, CN, 519000
JP Bunkyo-ku, JP, 113-8677
JP Kobe-shi, JP, 650-0047
JP Kurume-shi, JP, 830-0011
JP Kyoto-shi, JP, 606-8507
JP Osaka-shi, JP, 541-8567
JP Sakai-shi, JP, 591-8555
JP Shinjuku-ku, JP, 162-8655
JP Wakayama-shi, JP, 641-8510
JP Yokohama-shi, JP, 236-0051
KR Cheongju-si, KR, 28644
KR Namdong-gu, KR, 21565
KR Seongnam-si, KR, 13496
KR Seoul, KR, 06351
KR Seoul, KR, 5505
KR Seoul, KR, 3722
KR Seoul, KR, 03080
KR Suwon, KR, 16247
KR Suwon-si, KR, 16499
SG Singapore, SG, 168583
TH Bangkok, TH, 10400
TH Bangkok, TH, 10330
TH Bangkok, TH, 10700
TH Banphaeo, TH, 74120
TW Liuying, TW, 736
TW Taichung, TW, 40447
TW Tainan, TW, 70403
TW Taipei, TW, 11217
TW Taipei, TW, 100
TW Taipei City, TW, 110
TW Taoyuan, TW, 00333
US, CA Santa Monica, CA, US, 90404
US, CA Santa Rosa, CA, US, 95403
US, GA Atlanta, GA, US, 30318
US, MD Baltimore, MD, US, 21231
US, TX Houston, TX, US, 77090
US, VA Fairfax, VA, US, 22031